<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599898</url>
  </required_header>
  <id_info>
    <org_study_id>EMC070048CTIL</org_study_id>
    <secondary_id>same as unique protocol ID</secondary_id>
    <nct_id>NCT00599898</nct_id>
  </id_info>
  <brief_title>Nifedipine Compared to Atosiban for Treating Preterm Labor</brief_title>
  <official_title>Nifedipine Compared to Atosiban for Treating Preterm Labor. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raed Salim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and the safety of nifedipine
      compared to atosiban for treating preterm labor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delaying labor</measure>
    <time_frame>for more than 48 hours after starting treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>drugs side effects</measure>
    <time_frame>within the first 48 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obstetrical (number of days to delivery, gestational age at delivery, mode of delivery)</measure>
    <time_frame>within 24 hours after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal (Apgar score, sepsis, IVH, NEC, RDS, DEATH)</measure>
    <time_frame>within 30 days from delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Labor, Premature</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gestational age between 24 to 34 weeks which had been documented by a definite LMP and
             sonography up to 20 weeks.

          2. All women fulfilled the criteria of preterm labor. The diagnosis of preterm labor
             required the presence of 4 uterine contractions or more over 30 minutes, each lasting
             at least 30 seconds, and documented cervical change. The cervical criteria were met
             when either of the following was present:

               1. Nulliparous women: a single cervical examination demonstrating dilatation of 0 cm
                  to 4 cm and effacement of at least 50%

               2. Multiparous women: a single cervical examination demonstrating dilatation of 1 cm
                  to 4 cm and effacement of at least 50%.

          3. Provision of written informed consent

        Exclusion Criteria:

          1. Chorioamnionitis

          2. Preterm rupture of membranes

          3. Vaginal bleeding

          4. Major fetal malformations

          5. Severe hypertensive disorders

          6. Intrauterine growth restriction (&lt; 5th percentile).

          7. Non-reassuring fetal heart rate

          8. Maternal contraindications

               1. Chronic hypertension

               2. Systolic blood pressure &lt; 90 mmHg

               3. Cardiovascular disease

               4. Elevated hepatic enzymes

          9. Congenital or acquired uterine malformation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gali Garmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek Medical Center, Afula, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol. 2003 Jun;43(3):192-8. Review.</citation>
    <PMID>14712983</PMID>
  </reference>
  <reference>
    <citation>Papatsonis DN, Van Geijn HP, Ad√®r HJ, Lange FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol. 1997 Aug;90(2):230-4.</citation>
    <PMID>9241299</PMID>
  </reference>
  <reference>
    <citation>Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, Liston RM, Dansereau J, Mazor M, Shalev E, Boucher M, Glezerman M, Zimmer EZ, Rabinovici J. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000 May;182(5):1191-9.</citation>
    <PMID>10819857</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Raed Salim</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Preterm labor</keyword>
  <keyword>Atosiban</keyword>
  <keyword>Nifedipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

